GSK's Blenrep (belantamab mafodotin) Receives EC's Approval for R/R Multiple Myeloma
Shots:
- The EC’s approval is based on DREAMM-2 study assessing Blenrep (2.5/ 3.4 mg/kg- q3w) as monothx. in adult patients prior treated with 4 therapies and whose disease is refractory to at least one proteasome inhibitor- one immunomodulatory agent- and an anti-CD38 mAb- and who have demonstrated disease progression on the last therapy
- The data demonstrated that Blenrep (2.5 mg/kg dose- q3w) resulted in 32% ORR- mDoR (11mos.) & mOS (13.7mos.) while the safety and tolerability profile is consistent with previous data of the therapy
- Blenrep is a BCMA mAb conjugated to the cytotoxic agent auristatin F via a non-cleavable linker and has received EMA’s PRIME designation in 2017
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com